Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078961 · ClinicalTrials.gov registry record · Phase 1
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01078961: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01078961 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01078961, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study involves the use of two investigational drugs: sorafenib and bortezomib. Sorafenib is designed to stop the growth of cells caused by changes associated with cancer. Bortezomib is designed to stop cancer cells from getting rid of waste products. This causes the cells to build up toxic levels of waste that leads to cell death. In the laboratory, the combination of sorafenib and bortezomib has been shown to fight cancer cells better than either drug alone. We are looking to determine if the combination of sorafenib and bortezomib is a safe treatment for patients with advanced melanoma. The effectiveness of this combination will also be assessed.
Interventions
- DRUG sorafenib
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078961
The ClinicalTrials.gov registry entry for NCT01078961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sorafenib is the first listed.
NCT01078961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078961 about?
NCT01078961 is a clinical study titled "An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma". This research study involves the use of two investigational drugs: sorafenib and bortezomib. Sorafenib is designed to stop the growth of cells caused by changes associated with cancer. Bortezomib is designed to stop cancer cells from getting rid of waste products. This causes the cells to build up t...
What is the current status of trial NCT01078961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01078961?
The interventions under investigation include: sorafenib (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT01078961?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.